Serum and urine samples had been collected for measurement of angiogenic peptides. Forty eight patients were enrolled. Twenty eight sufferers had glioblastomas, and 20 had anaplastic gliomas. The median age was 53 years, as well as median KPS was 70. Thirty two percent of individuals had undergone 1 previ ous chemotherapy treatment, 34% had two, and 34% had three or more preceding chemotherapies. The treatment was reasonably properly tolerated in this heavily pretreated population. No treatment method linked deaths occurred. Fatigue was frequent but usually mild. Two percent of sufferers had a partial response, 9% had a minor response, 59% had stable disorder, and 30% progressed at their first scan. For GBM individuals, the median progression absolutely free survival time was eleven weeks, the six month PFS fee was 9%, and also the median all round survival time was 21 weeks. For AG individuals, the median PFS time was 14 weeks, the six month PFS rate was 26%, as well as median OS time was 41.
5 weeks. When evaluating respond ers with non responders, there was a substantial variation in OS with median level estimates for responders and non responders of 33 and twenty weeks, respectively, selleckchem PFS was also signifi cantly various with 6 month PFS estimates of 21% vs. 0% inside the responder selleck chemical tgf beta receptor inhibitors as well as the non responder groups, respectively. A number of the patients had adequate serial serum or urine specimens for angiogenic peptide analysis. On this constrained set, serum and urine angiogenic peptides didn’t correlate with response or survival. This 4 drug, oral antiangiogenic chemotherapy regimen was effectively tolerated. Angiogenic peptide levels didn’t correlate with survival or response. Although there have been some responders, the routine did not considerably strengthen OS in this heavily pretreated group of patients who had been frequently not eligible for con ventional protocols.
Further research utilizing antiangiogenic chemotherapy mixed with far more potent antiangiogenic agents in sufferers with significantly less sophisticated disease could be warranted.

TA 28. A PHASE II STUDY OF RADIATION WITH CONCOMITANT AND THEN SEQUENTIAL TEMOZOLOMIDE IN Patients WITH NEWLY DIAGNOSED SUPRATENTORIAL HIGH GRADE MALIGNANT GLIOMA WHO HAVE UNDERGONE SURGERY WITH CARMUSTINE WAFER INSERTION R. V. La Rocca, J. Hodes, W. G. Villanueva, T. W. Vitaz, D. J. Morassutti, M. J. Doyle, S. Glisson, A.